Clinical Trials
Participation in clinical research advances our knowledge of effective treatments and helps us understand the life cycle of diseases.
Inspire Santa Fe Medical is committed to offering our patients the latest treatments through our clinical research division. Every clinical study is monitored and closely follows all FDA clinical practice guidelines for investigating the efficacy of new medications not yet on the market, as well as new uses for existing medications on the market.
Inclusion and involvement in any clinical study are voluntary and may be discontinued at any time by either the participant or study sponsor. Study participants are provided full disclosure of the study parameters, purpose, duration, and side effects If you are interested in learning more about a current trial or upcoming research participation opportunities, please contact us. Our experienced research team will be happy to discuss and answer questions you or your family may have about study objectives.
We are actively recruiting for the following clinical trials:
Horizon HZNP-KRY-403: A Phase 4, Multicenter, Open-Label, Infusion Duration Study to Assess Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrollable Gout Receiving Methotrexate.
Novartis CAIN457P12301—A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis
If you are interested in participation, please contact our Clinical Research Coordinator for further information:
(505)-908-3807
alundquist@sfrheumatology.com
We are participating in the following trials, but recruitment has ended:
Lilly-I4V-MC-JAJA: A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Horizon HZNP-KRY-202: A Phase 2, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA® (Pegloticase) (MIRROR)
